Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2008-03-18
2008-03-18
Belyavskyi, Michail (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100, C424S155100
Reexamination Certificate
active
10481212
ABSTRACT:
The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody.
REFERENCES:
patent: 6632927 (2003-10-01), Adair et al.
Walker et al Adv.Med Biol, 1985, vol. 186, pp. 833-841.
Feldman et al ., Transplant. Proc. 1998, 30, 4126-4127).
Cochlovius et al Modern Drug Discovery, 2003, pp. 33-38.
Paul, Fundamental Immunology, (textbook), 1999, under the heading Immunoglobulins: Structure and Function, , pp. 37, 43, 58, 59.
Rudikoff et al ., Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Ozaki et al., Blood, 1999, V.11, pp. 3922-3930.
Siami et al., Therapeutic Aphreresis, 1999, V. 3, pp. 8-19.
Boux, H. et al. “A tumor associated antigen specific for kappa myeloma cell.” J. Exp. Med., 158/5 pp. 1769-1774 (1983).
Dunn, R. et al. “Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.” Immunotechnology, 2/3 pp. 229-240 (1996).
Izard, M. et al., “An improved method for labeling Monoclonal Antibodies with Samarium-153: Use of the Bifunctional Chelate 2-(p-Isothiocyanatobenzl)-6-methyldiethylenetriaminepentaacetic Acid.” Bioconjugate Chem 3 /4 pp. 346-350 (1992).
Walker, K. et al., “A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has potential as a therapeutic agent.” Adv. Exp Med. Biol., vol. 186 pp. 833-841 (19850.
Walker, K et al., “A rat model system for radioimmunodetection of kappa myeloma antigen on malignant B cells.” Europ. J. Med 12/9 pp. 461-467 (1986).
Weston K. et al. “In vivo binding of mouse IgG via polyreactive surface IgM abrogates progressive lymphocytosis in prolymphocytic leukemia.” Leukemia and Lymphoma, vol. 29, pp. 361-373 (1998).
Axiak SM et al. “Quantitation of freeκlight chains in serum and urine using a monoclonal antibody based inhibition enzyme-linked immunoassay”, Journal of Immunological Methods (1987) vol. 99 (1) pp. 141-147.
Boux HA et al. “The surface expression of a tumor-associated antigen on human kappa myeloma cells”, Eur. J. Immunol. (1984) 14:216-222.
Chauhan, D. and Anderson KC. “Apoptosis in Multiple Myeloma: Therapeutic Implications”, (2001) Apoptosis. 6 (1-2): 47-55.
Drach, J. et al. “The Biology of Multiple Myeloma”, (2000) Cancer Res Clin Oncol. 126:441-447.
Drayson, M. “Serum Free Light-Chain Measurements for Identifying and Monitoring Patients with Nonsecretory Multiple Myeloma” (2001) Blood 97 (9):2900-2902.
Goodnow et al. “Structural Analysis of the Myeloma-Associated Membrane Antigen KMA”,(1985) J. Immunol. 135:1276-1280.
Kyle, RA. et al. “Update on the Treatment of Multiple Myeloma” (2001) The Oncologist. 6 (2):119-124.
Kyle, RA. “Clinical Aspects of Multiple Myeloma and Related Disorders Including Amyloidosis”, (1999) Path Biol. 47(2):148-157.
Ludwig, H. et al. “Multiple Myeloma: An Update on Biology and Treatment”, (1999) Annals Oncol. 10 (6):S31.
Tutt, Alison L. et al. “Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors”, (1998) J. Immunol., 161:3176-3185.
Ellis, Jonathan H. J. et al. “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma”, J. Immunol. (1995) 155: 925-937.
Maloney, David G. et al., “Antibody Therapy for Treatment of Multiple Myeloma”, Seminars In Hema., (1999), 36(1):30-33.
Choo Boon Hwa Andre
Dunn Rosanne Dorothy
Raison Robert Lindsay
Belyavskyi Michail
Bozicevic Field & Francis LLP
Francis Carol L.
Immune System Therapeutics Ltd
LandOfFree
Method for treating multiple myeloma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating multiple myeloma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating multiple myeloma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3906057